Connor, Clark & Lunn Investment Management Ltd. Vanda Pharmaceuticals Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.8 Billion
- Q1 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 692,878 shares of VNDA stock, worth $3.91 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
692,878
Previous 265,449
161.02%
Holding current value
$3.91 Million
Previous $1.12 Million
154.2%
% of portfolio
0.01%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding VNDA
# of Institutions
147Shares Held
49.6MCall Options Held
49.1KPut Options Held
107K-
Black Rock Inc. New York, NY8.14MShares$46 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny4.28MShares$24.2 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.4MShares$19.2 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.37MShares$13.4 Million0.03% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.8MShares$10.2 Million0.01% of portfolio
About Vanda Pharmaceuticals Inc.
- Ticker VNDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,561,500
- Market Cap $320M
- Description
- Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...